TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01384058
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe 10 mg per day for six weeks
Study: NCT04094584
Drug: Vivitrol (Extended Release Naltrexone)
Normalized name: naltrexone Injection [Vivitrol]
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
Study: NCT00953394
Drug: continuous 5 fluouracil infusion plus long-acting octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
Study: NCT00641082
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg for 48 weeks
Study: NCT00641082
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg for 48 weeks
Study: NCT02686476
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
Study: NCT01231412
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT01231412
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01231412
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00549770
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01231412
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04264143
Drug: Infusate with MTX110 and gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
Study: NCT00530920
Drug: tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00530920
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03245021
Drug: Opdivo
Normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles
Study: NCT02056171
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
Study: NCT01767792
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance).
Study: NCT03688555
Drug: ACT-774312
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
Study: NCT02803996
Drug: Aramchol
Normalized name: Aramchol
DrugBank: Aramchol (DB11860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
Study: NCT01940393
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration
Study: NCT01940393
Drug: Desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Administration
Study: NCT01940393
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration
Study: NCT01940393
Drug: Ebastine
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administration
Study: NCT01940393
Drug: Bilastine
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Drug administration
Study: NCT03337724
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Study: NCT03337724
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Study: NCT00674141
Drug: Dexamethasone soduim phosphate
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
Study: NCT01275014
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
Study: NCT03499730
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
Study: NCT04737096
Drug: DAOIB
Normalized name: Dapagliflozin and Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
Study: NCT00400816
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
Study: NCT00117910
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02066129
Drug: Fluticasone 44 mcg
Normalized name: fluticasone 44 mcg/inh inhalation powder
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone is an inhaled corticosteroid
Study: NCT02066129
Drug: Fluticasone 220 mcg
Normalized name: fluticasone 220 mcg/inh inhalation aerosol
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone is an inhaled corticosteroid
Study: NCT03119012
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75mg/day
Study: NCT03119012
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120mg/day
Study: NCT03119012
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/day
Study: NCT02914509
Drug: Travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02737865
Drug: Sonazoid
Normalized name: Sonazoid
DrugBank: Perflubutane (DB12821)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonazoid: Commercially available contrast material for ultrasonography
Study: NCT00582894
Drug: Busulfex, Fludarabine, ALemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
Study: NCT02704598
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
Study: NCT02704598
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
Study: NCT00151892
Drug: Asacol
Normalized name: Asacol
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.6g/day administered 800 mg Twice Daily (BID)
Study: NCT00150761
Drug: Levocetirizine (drug)
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00909597
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg po once daily for 4 weeks, followed by 45mg once daily
Study: NCT00909597
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg sc once weekly
Study: NCT00909597
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
Study: NCT00501891
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab administered intravenously 10mg/kg every other week.
Study: NCT00501891
Drug: Metronomic Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 50mg/m2 given orally on a daily basis.
Study: NCT01970202
Drug: 40mg Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
Study: NCT01970202
Drug: 60mg Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
Study: NCT00073840
Drug: levalbuterol
Normalized name: Levalbuterol
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID
Study: NCT02541786
Drug: dexlansoprazole based triple therapy
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
Study: NCT02541786
Drug: rabeprazole-based triple therapy
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
Study: NCT00358839
Drug: CGRP
Normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01277315
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
Study: NCT00495378
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02707640
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
Study: NCT02544997
Drug: Poziotinib
Normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg P.O. for 2wks q21days
Study: NCT02707640
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
Study: NCT02544893
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 ml 0.5 %bupivacaine is applied paravertebral space
Study: NCT02544893
Drug: dexmedetomidin
Normalized name: Dexmedetomidin
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
Study: NCT02544893
Drug: serum physiologic
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 ml serum physiologic is applied paravertebral space
Study: NCT03958708
Drug: Rifaximin 550 MG
Normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
Study: NCT02517905
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration
Study: NCT02557984
Drug: Amisulpride
Normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg Amisulpride
Study: NCT02557984
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg Naltrexone
Study: NCT01600053
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
Study: NCT00127335
Drug: cellulose placebo vs. atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug
Study: NCT01642758
Drug: Sodium 2,2 dimethylbutyrate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
Study: NCT01678534
Drug: Allogenic mesenchymal stem cells from adipose tissue
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04114058
Drug: liposomal bupivicaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local field infiltration
Study: NCT03501979
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib study drug is given in tablet form and taken daily.
Study: NCT03501979
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
Study: NCT03011645
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by mouth, single dose of 60 mg.
Study: NCT03011645
Drug: Lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by mouth, single dose of 20 mg.
Study: NCT00818259
Drug: Experimental: aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aprepitant powder for suspension, 125 mg/sachet, PO
Study: NCT00818259
Drug: Experimental: fosaprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
Study: NCT00818259
Drug: Comparator: ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron solution for infusion, IV, administered per local standard of care
Study: NCT00818259
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron solution for infusion, IV, administered per local standard of care
Study: NCT00818259
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone solution for infusion, IV, administered per local standard of care
Study: NCT01357811
Drug: eliglustat; digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
Study: NCT01357811
Drug: digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 0.25mg dose of digoxin (single dose) on Day 1
Study: NCT02867007
Drug: KHK2455
Normalized name: KHK2455
DrugBank: KHK2455 (DB17524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosing
Study: NCT02867007
Drug: Mogamulizumab
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: i.v. administration
Study: NCT02129673
Drug: VS101 Insert Dose C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained release of latanoprost into the eye
Study: NCT02129673
Drug: Latanoprost 0.005% eye drops
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 0.005% eye drops administered once daily on the eye
Study: NCT01868360
Drug: Subconjunctival aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subconjunctival aflibercept injection
Study: NCT03258372
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
Study: NCT01639326
Drug: Irinotecan high doses
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
Study: NCT01639326
Drug: Irinotecan standard doses
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
Study: NCT03372941
Drug: Dalbavancin
Normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
Study: NCT01926626
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Study: NCT01926626
Drug: Moclobemide
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)
Study: NCT02117687
Drug: carboxymethylcellulose 0.5%/glycerin 0.9%
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Study: NCT02117687
Drug: sodium hyaluronate 0.18%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
Study: NCT00448292
Drug: PRX-00023
Normalized name: PRX-03140
DrugBank: PRX-03140 (DB05596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.